(Q36614243)

15 August 2017

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen (English)

1 reference

15 August 2017

1 reference

1 reference

5

T Demkow

1 reference

15 August 2017

S Culine

1

1 reference

15 August 2017

C Theodore

2

1 reference

15 August 2017

M De Santis

3

1 reference

15 August 2017

B Bui

4

1 reference

15 August 2017

J Lorenz

6

1 reference

15 August 2017

F Rolland

7

1 reference

15 August 2017

F-M Delgado

8

1 reference

15 August 2017

B Longerey

9

1 reference

15 August 2017

N James

10

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

94

1 reference

15 August 2017

10

1 reference

15 August 2017

1395-1401

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603118

15 August 2017

0 references

cites work

Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361290

Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361290

Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361290

The present and future of combination chemotherapy in bladder cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361290

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361290

Single agent 2',2'-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361290

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361290

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361290

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361290

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361290

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361290

Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361290

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361290

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361290

Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361290

Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361290

Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361290

Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361290

Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium

20 September 2018

1 reference

12 December 2020

One-sample multiple testing procedure for phase II clinical trials

1 reference

12 December 2020

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

12 December 2020

Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer

1 reference

12 December 2020

Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid

1 reference

12 December 2020

Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts

1 reference

12 December 2020

Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer

1 reference

12 December 2020

Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603118

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.BJC.6603118

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

16622447

1 reference